Friday File: Annual Review Part Six (done!)

by Travis Johnson, Stock Gumshoe | February 27, 2020 8:01 pm

Finishing up the Annual Review, including some buys and sells and updates on The Trade Desk, Tiptree, Keysight, Fairfax, Kennedy-Wilson, Innovative Industrial Properties, II-VI, Guardant Health, Fibra Uno, Disney, Crown Castle, Africa Oil and more...

This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.

Source URL: https://www.stockgumshoe.com/2020/02/friday-file-annual-review-part-six-done/


11 responses to “Friday File: Annual Review Part Six (done!)”

  1. martii says:

    Happy Birthday! And thanks for the great info

  2. larkn1412 says:

    as always, very informative Travis, thanks. Like you I find NOK a real puzzle.. its like that gifted boy in the class who has the brains and sporting talent to really succeed but just doesnt seem to get on with it …..I sort of get the feeling that the almost see their glory days as being past and with a dejected shrug of the shoulders ” so this is what our business has become”. Hopefully they can turn it around… I have a few long calls on them . Cant help notice your singularly bereft of mining stocks .. dont like em or haven’t found a partner you consider dancing with yet ? Dont worry the next question along those lines is not going to be about crypto.. LOL

  3. cjagadis says:

    Thanks for an excellent update.Enjoy your vacation.

  4. meridian says:

    I must admit I’m mostly running for the exits. I’m not sitting on big gains to start with, and sitting on increasing losses could keep me up at night. Maybe I’ll have to buy back in a bit higher, but maybe I’ll be able to buy back in a lot lower. I agree that once coronavirus is everywhere, life will return to almost-normal fairly quickly, but if stocks were in at least a bit of a bubble (due to increasing debt levels, high valuations, etc), and looking for a needle, maybe they found it.

  5. Investor Clouseau says:

    Have a great trip! As always it’s been a pleasure to read your annual portfolio comb-through. I think its pending short summary is probably my favorite thing about StockGumshoe and it really helps me frame my investment outlook. Trading along those lines with the mad money in my Robinhood account for the first half of 2019 allowed me to cash out that summer and sink the profits in some much needed home upgrades.

    I’ll be ready to re-start my Robinhood for-fun portfolio again soon, but I’ve also been adding some of the more conservative and long term Gumshoe bets to my Roth IRA portfolio in tiny increments. thanks to Vanguard going commission free.

    I’ve learned a lot, and am so glad I stumbled upon your site a year or two ago. Coupled with the recent commission free phenomenon it’s allowed me to tackle investing with the right frame of mind and confidence through bite sized chunks since I’ve got a small budget to work with.

  6. jazzroxy says:

    Travis, Always appreciate your take on things – I’d be curious to hear your thoughts over the weekend (or whenever) on how you evaluate which of your current – or new – positions you choose to add to upon this type of drastic correction that we had this week… it feels like everything is “on sale” , unless of course the virus shows up in the NYC subway system and wall street faints… Thanks!

  7. rohtsc711 says:

    Most of our readers would appreciate your insight on the deluge of coronavirus stocks dominating the market.
    “CODX”, maker of diagnostic kits for Covid-19 could go vertical once approved by FDA/CDC. The stock has already jumped 400% on news that their patented test kits offer results in 45-min, as opposed to 48-hours to send samples for testing at various state labs. They also advertise to be more accurate than the CDC tests, which have already given some “false-positives”.
    “TOMZ”, is also under the radar, maker of sterilization machines, already approved/adopted by China. Could be in high demand if the virus spreads as rapidly in the U.S.
    There is a slew of vaccine makers jumping on the bandwagon to develop a successful vaccine, but to the victor will go the spoils of that race. Even Israel has recently promised they will have a valid vaccine in “weeks”, but most virologist view that as a small miracle since animal testing, human testing Phase I/II/III would require months per phase before approval for mass production.

  8. fngwave says:

    Hello All, hope u are all ok with this virus going around
    I can across a stat on Apple put Mar 20, 2020. Was at 6.76 – 8.25. Would appreciate your take on this,

  9. leesal says:

    FYI: Analyst Ophir Gottlieb with https://pro.cmlviz.com/premium-news reports:

    Re: TTD A company growing revenue at nearly 40% and actual earnings at 23% is literally unprecedented for any technology company in the United States with over $600 million in revenue and at least $100 million in net income.

    The rule of thumb for software companies is called ‘the rule of 40.’ If revenue growth rate + net income margin % is greater than 40, then you have a company that sits in the hyper growth realm and deserves a higher valuation than peers.

    TTD is at 39% (revenue growth) + 24% (GAAP Net income margin) = 63%. Far and away better than the rule of 40. TTD has a new space, “the rule of 60.” TTD sits in the hyper growth realm and deserves a higher valuation than peers.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.